Conditions: Diabetes Mellitus, Insulin-Dependent Hypercholesterolemia
Keywords: Type 1 diabetes Children Statins Hypercholesterolemia Lipoproteins C reactive protein Continuous glucose monitors Adolescence Abdominal magnetic resonance imaging Toll like receptors Receptors of advanced glycation end products Nutrition
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 42
Healthy volunteers: yes

Brief summary:
Children with type1 diabetes (T1DM) have increased risk for cardiovascular disease (CVD) due to chronic increase in the blood sugars and inflammation. If there is also increased in cholesterol, it creates a highly abnormal environment not fully corrected by improved control of the blood sugars. CVD remains the principal risk of mortality in T1DM, and its prevention and treatment, compelling in children. This grant proposal encompasses 3 separate, yet interrelated projects addressing different aspects of CVD risk in children with T1DM. Project #1: a randomized controlled trial on the safety and efficacy of a class of drugs called "statins", which lower bad cholesterol in the body, in children with diabetes and elevated bad cholesterol. We will measure changes in concentration of blood inflammatory markers and for the 1st time, correlate levels of these markers with changes in blood sugar as measured by continuous glucose sensors, instruments that measure the blood sugar continuously through a small needle under the skin. Project #2: is a laboratory study to investigate the genetics and concentration of key molecules that participate in the inflammatory cascade and atheromatous plaque formation that causes CVD. Expression levels in children with T1DM will be compared with those in healthy controls for the 1st time. Project #3: examines the use of abdominal aortic MRI to measure damage to the arteries in children with T1DM and healthy age-matched controls. The results of these studies will likely provide important new data on the use of statins in children with diabetes.

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: Atorvastatin intervention 2: Atorvastatin Placebo
Intervention descriptions: intervention 1: 10 or 20 mg daily intervention 2: 10 or 20 mg daily

Protocol document: